The algorithms for treating psoriatic arthritis ( PsA ) are unique among rheumatic diseases because most PsA patients receive prior treatment by dermatologists for psoriasis, with many of the same therapies that are frequently used for PsA . Therefore, biologic and targeted synthetic DMARD s are more frequently used as early-line therapies after the diagnosis of PsA . Understanding the use of non- TNF inhibitors, namely, IL -12/23 inhibitors, IL -17 inhibitors, and PDE -4 inhibitors, is crucial for pharmaceutical companies to properly manage their brands in the PsA market. Claims data analysis provides an objective lens to see how physicians prescribe therapies and reveals real-world data on persistency and compliance of the PsA therapies.


Related Reports

Psoriatic Arthritis - Landscape & Forecast - Disease Landscape & Forecast

A series of launches are expected to continue to impact the increasingly dynamic psoriatic arthritis (PsA) therapy market in the next ten years and...

View Details

Psoriatic Arthritis | Disease Landscape and Forecast | G7 | 2020

A series of launches are expected to impact the increasingly dynamic psoriatic arthritis (PsA) therapy market over the next 10 years and challenge the dominance of the TNF inhibitors; the...

View Details

Psoriatic Arthritis - Current Treatment - Detailed, Expanded Analysis: Treatment Algorithms - Claims Data Analysis (US) Dashboard

Treatment of psoriatic arthritis (PsA) typically begins with conventional disease-modifying antirheumatic drugs (

View Details

Psoriatic Arthritis - Current Treatment - Detailed, Expanded Analysis: Treatment Algorithms - Claims Data Analysis (US)

Treatment of psoriatic arthritis (PsA) typically begins with conventional disease-modifying antirheumatic drugs (

View Details